Skip to main content

Small Pharma Inc(DMT-X)
TSX Venture

Today's Change
Real-Time Last Update

Stocks in play: Small Pharma Inc.

Baystreet - Wed Jan 25, 8:47AM CST

Announces that SPL026, intravenous N,N-Dimethyltryptamine, with supportive therapy for the treatment of Major Depressive Disorder met the primary endpoint in its Phase IIa clinical trial, demonstrating a statistically significant and clinically relevant reduction in depressive symptoms at two-weeks post-dose, as compared to placebo. Further analysis of key secondary endpoints demonstrated a rapid and durable antidepressant effect to 12-weeks. Small Pharma Inc. shares V.DMT are trading unchanged at $0.10.

Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.